Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer
Mené sur 74 patients atteints d'un cancer du poumon non à petites cellules récidivant, cet essai de phase I évalue la dose maximale tolérée, l'activité antitumorale, la toxicité et le taux de réponse objective du rovalpituzumab tésirine, un immunoconjugué associant un anticorps monoclonal ciblant DLL3 et un agent chimiothérapeutique, après l'échec d'un ou de deux protocoles de chimiothérapies
DLL3—an atypical inhibitor of the Notch ligand—has been identified in tumour-initiating cells isolated from small-cell lung cancer. It is expressed on the surface of tumour cells in about 85% of patients with small-cell lung cancer and large-cell neuroendocrine cancer, but not in healthy tissues and non-neuroendocrine tumours.1 DLL3 is a novel and promising target for development of specific inhibitors to treat patients with small-cell lung cancer.
The Lancet Oncology , commentaire, 2015